Xiaozhe Wan

机构：Huawei Technologies (China), Huawei Technologies (United Kingdom)

发表论文 19 篇 · 总被引 1888 次 · h-index 11

代表论文

• Pushing the Boundaries of Molecular Representation for Drug Discovery with the Graph Attention Mechanism (2019 · Journal of Medicinal Chemistry · 被引 1063)
• Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor (2018 · Cancer Science · 被引 372)
• Deep Learning Enhancing Kinome-Wide Polypharmacology Profiling: Model Construction and Experiment Validation (2019 · Journal of Medicinal Chemistry · 被引 104)
• Discovery of Pyrazolo[3,4- d ]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation (2021 · Journal of Medicinal Chemistry · 被引 63)
• Optimizing chemical reaction conditions using deep learning: a case study for the Suzuki–Miyaura cross-coupling reaction (2020 · Organic Chemistry Frontiers · 被引 56)
• Drug target inference by mining transcriptional data using a novel graph convolutional network framework (2021 · Protein & Cell · 被引 52)